Pipeline

Silver Creek’s purpose is to deliver Smart Growth Factors™ to the clinic that will help patients who suffer organ damage resulting from an acute injury. Scp776 is Silver Creek’s lead program and is under active clinical development for stroke.

Pipeline

Silver Creek’s purpose is to deliver Smart Growth Factors™ to the clinic that will help patients who suffer organ damage resulting from an acute injury. Scp776 is Silver Creek’s lead program and is under active clinical development for stroke.

Our pipeline

Therapeutic

Pre-clinical

Phase 1

Phase 2

Phase 3

Untitled

scp776

Scp776 is our flagship Smart Growth Factor™ under development for the treatment of Acute Ischemic Stroke. Scp776 demonstrated safety and therapeutic benefit in an NHP tMCAO model of ischemic stroke.

Development Stage: Phase 1 studies have been completed. The Phase 2a/2b ARPEGGIO trial will begin Q2 2022.

Indication: Acute Ischemic Stroke

scp776

Scp776 is our flagship Smart Growth Factor™ under development for the treatment of Acute Ischemic Stroke. Scp776 demonstrated safety and therapeutic benefit in an NHP tMCAO model of ischemic stroke.

Development Stage: Phase 1 studies have been completed. The Phase 2a/2b ARPEGGIO trial will begin Q2 2022.

Indication: Acute Ischemic Stroke

scp787

Scp787 is a topical formulation of a Smart Growth Factor™ in development for cosmetic dermatology applications.

Development Stage: Pre-clinical large animal studies have been completed.

Indication: Cosmetic Dermatology

scp787

Scp787 is a topical formulation of a Smart Growth Factor™ in development for cosmetic dermatology applications.

Development Stage: Pre-clinical large animal studies have been completed.

Indication: Cosmetic Dermatology

scp791

Scp791 is an intrathecal formulation of a Smart Growth Factor™ under development for the treatment of Parkinson's Disease.

Development Stage: Mechanism of action identified.

Indication: Parkinson's Disease

scp791

Scp791 is an intrathecal formulation of a Smart Growth Factor™ under development for the treatment of Parkinson's Disease.

Development Stage: Mechanism of action identified.

Indication: Parkinson's Disease